Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

The therapies’ availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.

UK biotech financing recovery was present in the private markets in Q2 2026 as the sector contends with a tough global funding landscape.

Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems.

Fraudulent and illegal conduct by pharmaceutical companies poses a great risk to public health and maligns the decisions of healthcare providers, costing billions of dollars to the government.

MSD (Merck & Co) has won US Food and Drug Administration (FDA) approval for its cholesterol-lowering pill, marking a significant milestone in the drugmaker’s push to reduce revenue reliance on ...

Cellares and Sonoma Biotherapeutics have partnered to automate the manufacturing of the latter’s SBT-77-7101 programme using the Cellares Cell Shuttle platform.

The FDA has issued traditional approval to Novartis for Fabhalta to slow the decline of kidney function in adults with primary IgAN who are at risk of disease progression.

The suite of tools is designed to allow AI to carry out R&D work more quickly, reliably, and in a continuous innovation loop.

Harbour BioMed and Kelun-Biotech have received approval from China’s NMPA for their IND application for the HBM7575/SKB575 bispecific antibody intended to treat asthma.

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine programme with the 4CMenB vaccine for adolescents.

Blood-based biomarkers could play a key role in detecting and treating Alzheimer’s early at the first point of contact, experts say.